Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05743049 · ClinicalTrials.gov registry record
Collection of Circulating Biomarkers in Pancreatic Cancer
A clinical trial of Pancreas Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT05743049 is a study of Pancreas Cancer that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 30 participants, below the 907-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05743049, a study of Pancreas Cancer, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This protocol will involve collection of blood samples from patients with a diagnosis of pancreatic adenocarcinoma for evaluation of circulating biomarkers.
Conditions Studied
Interventions
- OTHER Obtaining blood for analysis of various circulating biomarkers
Study Locations (1)
Pennsylvania
- Abramson Cancer Center at University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-02-27 |
| Est. Completion | 2028-01-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05743049
The ClinicalTrials.gov registry entry for NCT05743049 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 907-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreas Cancer appearing as the primary indexed condition, and to 1 intervention - of which Obtaining blood for analysis of various circulating biomarkers is the first listed.
NCT05743049 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05743049 about?
NCT05743049 is a clinical study titled "Collection of Circulating Biomarkers in Pancreatic Cancer". This protocol will involve collection of blood samples from patients with a diagnosis of pancreatic adenocarcinoma for evaluation of circulating biomarkers.
What is the current status of trial NCT05743049?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2023-02-27. Estimated completion is 2028-01-15.
What conditions does trial NCT05743049 study?
This clinical trial studies the following conditions: Pancreas Cancer.
What interventions are being tested in trial NCT05743049?
The interventions under investigation include: Obtaining blood for analysis of various circulating biomarkers (OTHER).
Who is sponsoring clinical trial NCT05743049?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05743049 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreas Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
RECRUITING
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
The Cancer of the Pancreas Screening-5 CAPS5)Study
RECRUITING · Phase 3
-
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.